Rasilez

Selected form

Aliskiren

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive

Treatment option: Hyperlipidemia, Hypertension, Diabetic Kidney Disease, Cerebrovascular Accident, Smoking, Smoking Cessation, Diabetes Mellitus, Heart Failure, Heart Attack

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rasilez

Quick Facts

Property	Description
Active Ingredient	Aliskiren (as Aliskiren hemifumarate)
Form	Film-coated tablet
Pharmacological Class	Direct Renin Inhibitor (DRI)
Common Use	Management of high blood pressure (hypertension)
Origin	Synthetic compound

Definition, Composition, and Form

Rasilez is a prescription pharmaceutical product whose single active substance is Aliskiren. This agent is a synthetic, non-peptide compound formulated for oral administration as a film-coated tablet (monotherapy), distinguishing it from older peptide-based inhibitors.

The identity of the medicine centers on its core component, Aliskiren hemifumarate. The consistent tablet form allows for reliable, systemic delivery of the active substance, which is clinically recognized for providing effective daily blood pressure control. This supports the use of Rasilez in adult patients requiring sustained daily cardiovascular management.

Pharmacological Class and Unique Action

Rasilez is classified as an Antihypertensive agent and specifically belongs to the unique, first-in-class category of Direct Renin Inhibitors (DRIs). This classification signifies its mechanism: it selectively targets and binds directly to the renin enzyme, the initiator of the body's powerful Renin-Angiotensin-Aldosterone System (RAAS).

This unique design leads to the blunting of the compensatory rise in plasma renin activity often seen with other RAAS blockers. This makes Aliskiren a dedicated intervention at the system's starting point, offering a distinct approach from later-acting medications like ACE inhibitors.

General Therapeutic Purpose and Benefit

The principal therapeutic purpose of Rasilez is the sustained reduction and management of high blood pressure (hypertension) in adult patients. By successfully interfering with the initial phase of the RAAS cascade, the medication promotes the relaxation and widening of blood vessels. This foundational control over the RAAS serves to decrease overall cardiovascular load and is a typical choice for patients whose hypertension may require dedicated intervention.

Regulatory References

NIH LiverTox Aliskiren

What side effects are possible with Rasilez?

The official safety profile for Rasilez (Aliskiren) documents the types and frequency of adverse reactions observed in clinical use and sets explicit limitations on the medicine's use, based on regulatory standards (FDA, EMA).

Frequency-Classified Adverse Reactions

Adverse effects are categorized by the estimated rate of occurrence as documented in the prescribing information:

Common (1% to 10%): The most frequently reported adverse events affect the gastrointestinal system, including diarrhea, abdominal pain, and dyspepsia. Rash is also classified as common.
Rare (less than 0.1%): Angioedema (swelling of the face, tongue, and/or throat) and symptomatic hypotension (low blood pressure) are formally listed as rare.
Frequency Not Known (Post-Marketing): Events reported after initial approval include acute renal failure, hyperkalemia (high potassium), anaphylactic reactions, and severe cutaneous adverse reactions such as Stevens Johnson syndrome.

Serious Safety Constraints

The most significant safety constraints are defined by specific patient populations and combination use:

Fetal Toxicity: Use during the second and third trimesters of pregnancy is contraindicated due to the risk of fetal injury and death, a restriction common to all agents that act directly on the Renin-Angiotensin System (RAS).
Dual RAS Blockade: The combination of Rasilez with an ACE inhibitor or an ARB is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR < 60 mL/min) due to an increased risk of hypotension, hyperkalemia, and worsening renal function.

Population and Contextual Notes

The label notes a higher rate of diarrhea in women and the elderly. Furthermore, patients with volume or salt depletion may experience symptomatic hypotension after starting treatment, and the label advises the periodic monitoring of serum potassium and renal function in susceptible individuals. The regulatory safety structure defines clear boundaries for the drug’s use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a Rasilez (Aliskiren) overdose identifies excessive hypotension (severely low blood pressure) as the most expected manifestation, stemming from the drug's action. This hemodynamic instability may lead to associated symptoms such as dizziness, fainting (syncope), and blurred vision. Gastrointestinal effects, including nausea, vomiting, and diarrhea, are also documented.

Life-Threatening Manifestations and Required Actions

Urgent medical assistance must be sought for any suspected overdose or if the following severe symptoms occur: collapse, seizure, trouble breathing, or inability to be awakened. A life-threatening outcome associated with Aliskiren is angioedema (swelling of the face, tongue, or larynx), which can cause fatal airway obstruction. The medication must be discontinued immediately if angioedema develops.

Official Management and Monitoring

Treatment is entirely symptomatic and supportive, as no specific antidote is known. For severe hypotension, official guidance describes procedures such as placing the patient in the supine position and administering intravenous fluid replacement. Overdose management may require prolonged observation, including periodic monitoring of renal function and serum electrolytes, due to the risk of complications like acute renal failure and hyperkalemia.

Therapeutic Uses of Rasilez

Rasilez (aliskiren) is a medication used to help manage elevated blood pressure, a condition also referred to as essential hypertension. It is utilized to support the maintenance of blood pressure within an appropriate range, which contributes to reducing the risk of cardiovascular events associated with chronic hypertension. The medicine may be administered alone or combined with other agents prescribed for managing blood pressure.

Quick Fact: Relief for Elevated Blood Pressure

Therapeutic use involves assisting individuals in controlling consistently high readings, which may be systolic or diastolic. This type of pharmacological support forms part of a comprehensive strategy aimed at achieving and sustaining a healthier vascular state.

“The goal of treatment with aliskiren is to assist patients in reaching their target blood pressure levels, which is vital for long-term heart and vascular health support.”

Eligibility and Restrictions for Use

Eligibility and Contraindications

The use of Rasilez (aliskiren) is strictly governed by established regulatory criteria concerning patient health status, concomitant medications, and physiological state.

The medicine is strictly contraindicated (must not be used) in the following populations:

Patients with Diabetes Mellitus who are simultaneously taking Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).
Patients with moderate-to-severe renal impairment (Glomerular Filtration Rate (GFR) < 60 mL/min/1.73 m^2) who are simultaneously taking ACEIs or ARBs.
Women who are in the second or third trimesters of pregnancy.
Patients with a known history of angioedema related to previous aliskiren treatment, or with hereditary/idiopathic angioedema.
Patients taking potent P-glycoprotein (P-gp) inhibitors (e.g., ciclosporin, itraconazole).

Additional Restrictions and Non-Recommended Use:

Children: Use is generally not established or recommended for children under 18 years of age, and is contraindicated for children under 2 years of age.
Renal Function: Use is not recommended in any patient with severe renal impairment (GFR < 30 mL/min/1.73 m^2).

What should I know about interactions with other medicines?

Documented Interactions with other Medicines and Products

Official regulatory information describes specific interaction patterns for aliskiren (Rasilez) based on effects on the body's Renin-Angiotensin-Aldosterone System (RAAS) and drug transport mechanisms.

Classification	Interacting Substance/Class	Official Regulatory Statement
Contraindicated Combinations	ACE Inhibitors or ARBs	Co-administration is formally contraindicated in patients with diabetes mellitus due to increased risks of hyperkalemia, renal impairment, and hypotension.
	Cyclosporine and Itraconazole	Use must be avoided due to the documented potential for large increases in aliskiren plasma concentrations via P-glycoprotein (P-gp) inhibition.
Pharmacodynamic Risk	Potassium Supplements or Diuretics	Concurrent use with potassium-sparing diuretics or supplements increases the documented risk of hyperkalemia (high potassium levels).
	NSAIDs	Co-administration is associated with a risk of worsening renal function and potential attenuation of the blood pressure-lowering effect.
Exposure-Altering Agents	Rifampin (P-gp Inducer)	Documented to substantially reduce aliskiren plasma concentration and exposure.
Dietary Interactions	High-fat Meals and Specific Juices	High-fat meals are documented to reduce aliskiren absorption. Ingestion of grapefruit, apple, or orange juice is also documented to lower aliskiren plasma concentrations. Patients should establish a routine pattern of administration with regard to meals.

Mechanism of Action

Rasilez (aliskiren) is classified as a direct renin inhibitor that acts specifically within the renin-angiotensin-aldosterone system (RAAS). Its biological target is the enzyme renin, which catalyzes the rate-limiting step of the cascade. Rasilez binds to the active site of renin, thereby inhibiting its enzymatic activity. This action prevents the cleavage of the substrate angiotensinogen into angiotensin I. The molecular consequence of reduced angiotensin I formation is a subsequent decrease in the circulating levels of the downstream effectors, angiotensin II and aldosterone. The system-level physiological modulation resulting from the decrease in angiotensin II is vasodilation and a reduction in sympathetic nervous system activation. Simultaneously, reduced aldosterone activity contributes to decreased sodium and water reabsorption in the distal nephron. This combined modulation leads to reduced systemic vascular resistance and effects on renal hemodynamics.

Dosage and Administration Information

Rasilez is a medication supplied as a film-coated tablet for oral use only. Administration focuses on establishing a fixed daily regimen and maintaining consistency to ensure predictable systemic delivery.

Standard Dosing and Titration

Treatment initiation typically involves a dose of 150 mg taken once daily. For individuals whose blood pressure remains insufficiently controlled after the initial treatment phase, the dose may be increased, or titrated, up to the authorized maximum daily dose of 300 mg. This dose adjustment is usually considered after the first two weeks, as the full antihypertensive effect is substantially attained within this period.

Timing and Administration Conditions

The medicine is scheduled for administration once daily and is intended to be taken at the same time each day for consistency. A crucial condition for proper use is maintaining a consistent temporal relationship with food; the tablet must be taken either always with food or always without food to standardize absorption. The tablet is to be swallowed whole with water. Furthermore, the consumption of grapefruit juice should be avoided during the period of use due to potential administration constraints.

Population-Specific Use

The prescribed profile indicates that the standard starting dose of 150 mg does not require initial adjustment for older adults (age 65 and over). Similarly, no initial dose modification is required for patients with mild to severe liver impairment or mild to moderate kidney impairment. If a dose is missed, the protocol is to continue with the next scheduled dose at the usual time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rasilez

Evidence for Use in Essential Hypertension

Clinical research for Rasilez (aliskiren) in the management of high blood pressure, known as essential hypertension, primarily consists of controlled studies where people were randomly assigned to receive either the medicine or an inactive substitute (placebo), or another established blood pressure medicine.

These studies were designed to see if Rasilez was studied for its ability to lower measurements of systolic and diastolic blood pressure readings. Studies examined blood pressure measurements when Rasilez was used by itself, and reported varying measurement shifts. Research explored the measurements of blood pressure when Rasilez was used in combination with other agents, and documented the observed changes.

What remains less clear from the research is the long-term impact of Rasilez alone on preventing major health problems often tracked in long-term health studies, such as heart attacks or strokes. While the studies recorded changes in blood pressure, research exploring long-term cardiovascular and mortality outcomes has been limited.

Studies in High-Risk Patients and Combination Regimens

Research has also explored the use of Rasilez in special populations, particularly those who have Type 2 diabetes along with existing kidney impairment and/or cardiovascular risk. These studies were large, long-term trials investigating whether adding Rasilez to standard medical treatment would affect outcomes for heart health and kidney function.

In these specific, high-risk groups, the key long-term outcome study findings for this combined approach indicated a lack of demonstrated benefit. One major trial was stopped early because the data suggested that adding Rasilez to another type of medicine (either an ACE inhibitor or an ARB) did not show a difference in the rate of composite cardiovascular or renal events compared to the control group. Furthermore, this combination in high-risk patients was associated with a higher frequency of certain events, including non-fatal stroke, renal adverse events, and hyperkalemia (high potassium levels), observed in the trial.

The research findings prompted regulatory authorities to issue specific warnings and cautions regarding the combined use of Rasilez with ACE inhibitors or ARBs in patients with diabetes or moderate to severe kidney impairment. The available evidence indicates that the primary outcome study did not find a difference in major long-term heart and kidney outcomes in this specific high-risk population.

Evidence in Special Populations

The research explored whether changes were observed in markers like B-type natriuretic peptide (BNP) in people with heart failure, and in measurements of heart muscle thickness (left ventricular hypertrophy, or LVH) in people with high blood pressure.

Studies reported observations of change in these markers, but larger, more comprehensive trials examining the frequency of major events like death or hospitalization for heart failure have not demonstrated a difference when Rasilez was added to standard treatment.

Additionally, the research on Rasilez in people with severe kidney impairment is limited, meaning that for people with the most advanced stages of kidney disease, data for this population remain insufficient to draw conclusions regarding long-term outcomes. There are also insufficient controlled clinical data for its use in patients with narrowing of the main artery to the kidney (renal artery stenosis). The evidence in children and adolescents is also not fully established, and clinical data are not fully established for use in those under the age of 18.

Frequently Asked Questions (FAQ)

Common questions about Rasilez (FAQ)

Q: How long does it usually take to notice the effects of Rasilez?

A: According to official product information, the maximal blood pressure-lowering effect of Rasilez is substantially observed after approximately two weeks of starting treatment. The full effect is not immediate, as it takes time for the medicine to fully modulate the body’s blood pressure system.

Q: Does Rasilez affect kidney function over time?

A: Official drug labels note the potential for impaired renal function (kidney problems) in certain individuals. Furthermore, acute renal failure has been reported in post-marketing experience. Regulatory documents note that monitoring of kidney function may be part of the care for individuals taking this medicine.

Q: Is Rasilez considered safe for use in older adults?

A: Clinical studies indicate that the initial dose of Rasilez typically does not require adjustment for older adults. However, official information notes that older patients are often more sensitive to the medicine’s effects. A general safety statement is not typically provided on the label; rather, specific considerations for this population are noted.

Q: Why is Rasilez sometimes prescribed with other blood pressure medicines?

A: Official regulatory documents explain that Rasilez may be used in conjunction with other antihypertensive agents, such as calcium channel blockers or diuretics. This combined approach is typically utilized to provide additional blood pressure control for patients whose pressure is not adequately managed by a single medicine alone.

Q: Is there a generic version of Rasilez available?

A: The active substance in Rasilez is aliskiren. Aliskiren is available in the United States under the brand name Tekturna, and in combination with other agents.

Q: Does Rasilez cause fatigue or tiredness in many users?

A: Regulatory-derived documents list fatigue (a feeling of tiredness) among the possible side effects of the medicine. However, the frequency of fatigue is not classified as common (1% to 10%) in official documentation.

Q: Are headaches a common side effect of Rasilez?

A: Headache is listed as a potential side effect in clinical trial reports or post-marketing data associated with the use of Rasilez. The frequency of headache is not classified as common (1% to 10%) in official product information documents.

Q: Does Rasilez interact with over-the-counter cold and flu medications?

A: Official drug labels advise that certain common components in over-the-counter medicines, such as anti-inflammatories (like NSAIDs), can interact with Rasilez. These interactions could potentially lead to a risk of worsening kidney function. It is important to be cautious about concurrent use of these product classes.

Q: Is it possible to take Rasilez at night instead of in the morning?

A: Official prescribing information states that the medicine should be taken once daily and that it is crucial to take it at the same time each day for consistency. The specific time of day (morning versus night) is not strictly mandated, but maintaining a consistent schedule is the most important factor for predictable absorption and effect.

Q: Is it safe to drive or operate machinery while taking Rasilez?

A: The official product information advises that caution should be exercised when driving or operating machinery while taking Rasilez. This is because side effects such as dizziness or fatigue may occur, which could potentially impair a person's ability to perform such tasks safely.

Q: What should I know about taking Rasilez if I have had kidney stones?

A: Official reporting from clinical studies indicates that renal stones (kidney stones) have been noted as an uncommon side effect associated with aliskiren use. This information is provided for educational purposes only and does not constitute individual medical advice.

Q: Is dizziness a temporary side effect or one that lasts?

A: Dizziness is a possible side effect, particularly in patients who have low levels of fluid or salt in their body. The product label states that patients experiencing dizziness are advised to lie down, as this may help prevent fainting. The official guidance states that persistent or severe symptoms should be communicated to a healthcare provider.

Q: Are there different brand names for the same medicine as Rasilez?

A: Rasilez contains the active substance aliskiren, which is also marketed under the brand name Tekturna in the United States.

Q: What does 'hypertension' mean in simple terms, in relation to Rasilez?

A: Hypertension is the medical term for high blood pressure, which is a condition where the force of blood pushing against the artery walls is too high. Rasilez works to reduce this pressure by acting on the body's natural system that controls blood vessel widening and blood pressure regulation.

Q: Is Rasilez a lifelong medication for high blood pressure?

A: For most patients, when starting treatment for high blood pressure, it is likely that the medication will need to be continued for the long term to maintain control. While this is the general expectation, a healthcare provider may adjust the dose or discontinue the medicine if blood pressure is well-controlled over an extended period.

Q: Are there any contraindications related to surgery while taking Rasilez?

A: Official prescribing information notes that patients with a history of airway surgery are at risk for severe complications from angioedema. Also, due to the drug’s action on the body's blood pressure system, a drop in blood pressure (hypotension) can occur during major surgery. Official information advises that patients communicate their use of this medicine to surgical teams.

How should Rasilez be stored and disposed of?

How to Store and Dispose of Rasilez (Aliskiren)

Official regulatory guidelines define specific conditions for the storage and disposal of Rasilez tablets.

Storage Requirements

Condition	Regulatory Rule
Temperature	Store at a temperature not above 30 C
Protection	Keep in the original package to ensure protection from moisture
Packaging	Must remain in the original container to maintain product stability
Child Safety	Store out of the sight and reach of children

Disposal Instructions

Unused Rasilez medicinal product or any resulting waste material must be disposed of in accordance with local requirements. This instruction ensures the proper handling and discarding of the product as defined by pharmaceutical waste protocols in a specific region.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.